Capmatinib (Tabrecta®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Update October 2022

Rothschedl, E. and Wolf, S. (2022): Capmatinib (Tabrecta®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Update October 2022. Oncology Fact Sheet Nr. 93.

[thumbnail of Oncology Fact Sheet Nr.93_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
106kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WF Respiratory system
Language:	English
Series Name:	Oncology Fact Sheet Nr. 93
Deposited on:	16 May 2022 10:25
Last Modified:	17 Oct 2022 11:44

Repository Staff Only: item control page